Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Operating Leases (2022 - 2025)

Caribou Biosciences has reported Operating Leases over the past 4 years, most recently at $27.2 million for Q4 2025.

  • Quarterly Operating Leases rose 8.64% to $27.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, up 8.64% year-over-year, with the annual reading at $27.2 million for FY2025, 8.64% up from the prior year.
  • Operating Leases was $27.2 million for Q4 2025 at Caribou Biosciences, up from $22.8 million in the prior quarter.
  • Over five years, Operating Leases peaked at $27.9 million in Q3 2022 and troughed at $22.8 million in Q3 2025.
  • The 4-year median for Operating Leases is $26.5 million (2023), against an average of $26.1 million.
  • The largest YoY upside for Operating Leases was 8.64% in 2025 against a maximum downside of 14.5% in 2025.
  • A 4-year view of Operating Leases shows it stood at $26.8 million in 2022, then dropped by 3.26% to $25.9 million in 2023, then dropped by 3.27% to $25.1 million in 2024, then rose by 8.64% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Operating Leases are $27.2 million (Q4 2025), $22.8 million (Q3 2025), and $23.6 million (Q2 2025).